Geron cuts 20 jobs, awaits imetelstat investigator results
This article was originally published in Scrip
Executive Summary
Geron has eliminated its drug discovery research and companion diagnostic programs, and reduced its work force by another 20 employees, and now the company's path forward depends solely on the results of an investigator-sponsored study for its lone drug candidate imetelstat in a single hematological indication.